NEVE ILAN, Israel, Nov. 25, 2020 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that the Company will host a live demonstration that will showcase the Nanox digital x-ray source tube and a range of 2D and 3D imaging applications performed by the Nanox.ARC at the 2020 Radiology Society of North America Virtual Annual Meeting. The live event will take place at the Nanox RSNA virtual booth on Thursday, December 3, 2020 at 11:00am E.T. An investor webinar will follow the live event on Thursday, December 3, 2020 at 2:00pm E.T.
The investor webinar will feature a replay of the recorded RSNA live steam and presentations of clinical applications of the Nanox.ARC system by well-known radiologists and their views of how they believe it will address a significant unmet need in medical imaging. The webinar will also feature a company presentation by CEO Ran Poliakine followed by a Q&A session.
“We are very much looking forward to debuting the Nanox technology and vision at this year’s RSNA Annual Meeting, as we believe this novel technology is poised to significantly expand and democratize the global medical imaging market,” stated Ran Poliakine, Chief Executive Officer of Nanox. “Legacy x-ray technology has evolved little since its discovery more than 120 years ago, and this analog technology is too costly and complex for mass deployment. We hope to change all that and look forward to demonstrating the technological capabilities that may be instrumental in changing the way we see preventive healthcare through mass availability of medical imaging devices around the world.”
Live demonstration at RSNA
Thursday, December 3
Interested parties can register for RSNA for a fee here.
Thursday, December 3
Interested parties may register for the investor webinar here.
Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and Nanox’s ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox’s expectations.
ReBlonde for Nanox